Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, U.O.S. Dipartimentale per la Diagnosi e la Terapia delle Coagulopatie, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Universita' degli Studi di Milano and Fondazione Luigi Villa, Milan, Italy.
J Thromb Haemost. 2013 Jul;11(7):1251-9. doi: 10.1111/jth.12280.
We characterized four unrelated patients with von Willebrand disease type 2A/IIE, sharing the same von Willebrand factor (VWF) in-frame deletion (p.[P1127_G1180delinsR];[=]) resulting from exon 26 skipping (Δ26).
To identify the VWF mutations and how they caused the mRNA splicing alteration, to evaluate the deletion by in vitro expression studies, and to assess whether or not the heterogeneity of the patients' phenotype might be related to a different degree of expression of the deleted subunit in patient plasma VWF.
Sequence analysis was performed with patient genomic DNA and platelet mRNA. Semiquantitative RT-PCR was also carried out to compare the expression of the wild-type (WT) and Δ26 alleles in the four patients. In silico analysis was performed with prediction splicing programs. Expression studies were performed to evaluate mutant recombinant VWF (rVWF) (Δ26 and Δ26/WT) as compared with WT rVWF.
Three patients shared the synonymous single-nucleotide substitution (SSS) c.[3390C>T];[=], whereas the novel mutation c.[3380-2A>G];[=] was present in the fourth patient. Semiquantitative RT-PCR of platelet mRNA revealed a different ratio of the WT and Δ26 alleles in the patients, consistent with the different VWF:FVIIIB values present in patient plasma. Expression studies confirmed reduced VWF-FVIII binding of rVWF-Δ26/WT.
SSS can induce alternative splicing, and those like c.3390C>T, which impact on the poorly conserved splicing regulatory elements, are difficult to predict, so that their role can be evaluated only by mRNA analysis. Moreover, these mutations seem to have different effects on the efficiency of alternative splicing, producing heterogeneous VWF variants among the four patients.
我们对四名无关联的血管性血友病 2A/IIE 型患者进行了研究,他们均存在第 26 外显子跳跃(Δ26)导致的血管性血友病因子(VWF)无义框缺失(p.[P1127_G1180delinsR];[=])。
鉴定 VWF 突变以及其导致 mRNA 剪接改变的方式,通过体外表达研究评估缺失情况,并评估患者表型的异质性是否与缺失亚基在患者血浆 VWF 中的表达程度不同有关。
使用患者基因组 DNA 和血小板 mRNA 进行序列分析。还进行了半定量 RT-PCR,以比较四名患者中野生型(WT)和 Δ26 等位基因的表达。使用预测剪接程序进行了计算机分析。通过与 WT rVWF 进行比较,进行了表达研究以评估突变重组 VWF(rVWF)(Δ26 和 Δ26/WT)。
三名患者共享同义单核苷酸取代(SSS)c.[3390C>T];[=],而第四位患者存在新的突变 c.[3380-2A>G];[=]。血小板 mRNA 的半定量 RT-PCR 显示,患者中 WT 和 Δ26 等位基因的比例不同,与患者血浆中存在的不同 VWF:FVIII 值一致。表达研究证实 rVWF-Δ26/WT 的 VWF-FVIII 结合减少。
SSS 可诱导可变剪接,而像 c.3390C>T 这样影响保守性差的剪接调控元件的突变难以预测,因此只能通过 mRNA 分析来评估其作用。此外,这些突变似乎对可变剪接的效率有不同的影响,在四名患者中产生了不同的 VWF 变体。